SPONSOR
Daiichi Sankyo
Total Trials
6
Recruiting
6
Phases
Phase 1, Phase 3
Conditions studied: Hepatic ImpairmentRecurrent or Metastatic Solid TumorsSolid TumorsSarcomaMetastatic Solid TumorsAdvanced Breast CancerMetastatic Breast CancerHER2 PositiveHR PositiveAdvanced Solid Tumor
Daiichi Sankyo is a clinical research sponsor with 6 registered studies on ClinicalTrials.gov, of which 6 are actively recruiting participants. Research covers conditions including Hepatic Impairment, Recurrent or Metastatic Solid Tumors, Solid Tumors, Sarcoma.
The trial portfolio spans Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Daiichi Sankyo
How many clinical trials has Daiichi Sankyo sponsored?
ClinicalMetric currently tracks 6 clinical trials sponsored by Daiichi Sankyo, of which 6 are actively recruiting participants. These trials cover conditions including Hepatic Impairment, Recurrent or Metastatic Solid Tumors, Solid Tumors. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Daiichi Sankyo research focus on?
Daiichi Sankyo clinical trials span Hepatic Impairment, Recurrent or Metastatic Solid Tumors, Solid Tumors, Sarcoma, Metastatic Solid Tumors, and additional conditions. The research pipeline includes Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Daiichi Sankyo clinical trial?
To participate in a Daiichi Sankyo trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Daiichi Sankyo trials with current recruitment status updated daily.
Clinical Trials by Daiichi Sankyo
NCT06740799 Phase 1
Recruiting
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Hepatic Impairment
NCT07015697 Phase 1
Recruiting
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Recurrent or Metastatic Solid Tumors
NCT06644755 Phase 1
Recruiting
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Solid Tumors
NCT07159126 Phase 1
Recruiting
A Study of DS3610a in Participants With Advanced Solid Tumor
Solid Tumors
NCT07683754 Phase 3
Recruiting
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Advanced Breast Cancer
NCT05765851 Phase 1
Recruiting
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology